ESMO Open

Published by: European Society for Medical Oncology  

People

  1. Motzer
    Motzer
  2. Abou-Alfa
    Abou-Alfa
  3. Drilon
    Drilon
  4. Argiles Martinez
    Argiles Martinez
  5. D'Angelo
    D'Angelo
  6. Ilson
    Ilson
  7. Jhaveri
    Jhaveri
  8. Modi
    Modi
  9. O'Reilly
    O'Reilly
  10. Rosenbaum
    Rosenbaum

Groups

  1. Department of Medicine (53)
  2. Solid Tumor Oncology Division (50)
  3. Gastrointestinal Oncology Service (15)
  4. Genitourinary Oncology Service (12)
  5. Thoracic Oncology (7)
  6. Breast Medicine Service (6)
  7. Hematologic Malignancies, Division of (6)
  8. Sarcoma Service (6)
  9. GSK Faculty (3)
  10. Gynecologic Medicine Service (3)
Search Within
Formats
  1. Journal Article (49)
  2. Review (8)
  3. Editorial (2)
  4. Miscellaneous (2)
  5. Correspondence (1)
Groups
  1. Department of Medicine (53)
  2. Solid Tumor Oncology Division (50)
  3. Gastrointestinal Oncology Service (15)
  4. Genitourinary Oncology Service (12)
  5. Thoracic Oncology (7)
  6. Breast Medicine Service (6)

More Groups

People
  1. Robert Motzer (8)
  2. Ghassan Abou-Alfa (5)
  3. Alexander Drilon (3)
  4. Rona Yaeger (3)
  5. Alison Schram (2)
  6. David Ilson (2)

More People

Years
  1. 2025 (8)
  2. 2024 (16)
  3. 2023 (9)
  4. 2022 (10)
  5. 2021 (7)
  6. 2020 (7)

More Years

Publishers
  1. European Society for Medical Oncology (62)

Results (62)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Health-related quality-of-life profile and clinical outcomes in first-line advanced renal cell carcinoma: A modeling analysis based on the CheckMate 9ER study
    Journal Article

    Cella, D.; Derosa, M.; Floden, L.; Giles, R. H.; Lothgren, M.; Ogareva, A.; Powles, T.; Purnajo, I.; Choueiri, T. K.; Bergerot, C.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab, in patients with advanced malignancies
    Journal Article

    Janku, F.; Tan, D. S. P.; Martin-Liberal, J.; Takahashi, S.; Geva, R.; Gucalp, A.; Razak, A.; Kan, R.; Reiners, R.; Mataraza, J.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer
    Journal Article

    Gouda, M. A.; Voss, M. H.; Tawbi, H.; Gordon, M.; Tykodi, S. S.; Lam, E. T.; Vaishampayan, U.; Tannir, N. M.; Chaves, J.; Nikolinakos, P.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer
    Journal Article

    Hong, D. S.; Xu, R. H.; Shen, L.; Dierselhuis, M. P.; Orbach, D.; McDermott, R.; Italiano, A.; Tahara, M.; Bernard-Gauthier, V.; Neu, N.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma
    Journal Article

    Lauer, U. M.; Awada, A.; Postel-Vinay, S.; Shapiro, G. I.; Thieblemont, C.; Piha-Paul, S. A.; Paik, P. K.; Shepard, D. R.; Docampo, L. I.; Galot, R.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Molecular tumour board in gastrointestinal cancers
    Journal Article

    Boscolo Bielo, L.; Crimini, E.; Repetto, M.; Barberis, M.; Battaiotto, E.; Katrini, J.; Martino, E.; Gaudio, G.; Lombardi, M.; Zanzottera, C.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors
    Journal Article

    Schram, A. M.; Boni, V.; Adjei, A. A.; Olszanski, A. J.; Vieito, M.; Francis, J. H.; Kurman, M.; Ahsan, J. M.; Tomkinson, B.; Garralda, E.
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: The phase II FRACTION gastric cancer study
    Journal Article

    Ku, G.; Haag, G. M.; Park, H.; Lam, V. K.; George, T. J.; Kim, S. S.; Gutierrez, M.; Shankaran, V.; Stein, S.; Denlinger, C. S.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: Results from the open-label, randomised, phase II FRACTION-RCC trial
    Journal Article

    Choueiri, T. K.; Kuzel, T. M.; Tykodi, S. S.; Verzoni, E.; Kluger, H.; Nair, S.; Perets, R.; George, S.; Gurney, H.; Pachynski, R. K.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save
  • Atezolizumab monotherapy for metastatic urothelial carcinoma: Final analysis from the phase II IMvigor210 trial
    Journal Article

    Rosenberg, J. E.; Galsky, M. D.; Powles, T.; Petrylak, D. P.; Bellmunt, J.; Loriot, Y.; Necchi, A.; Hoffman-Censits, J.; Perez-Gracia, J. L.; van der Heijden, M. S.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save

    • ESMO Open – authorized name for:

    Name ISSN / ISBN Publisher
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 20597029 The Authors
    ESMO Open 20597029 Unknown
    ESMO Open 20597029 The Pfizer, The Author(s)
    ESMO Open 2059-7029 Elsevier Inc.
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 20597029 The Author(s)
    ESMO Open 2059-7029 European Society for Medical Oncology
    ESMO Open 2059-7029 European Society for Medical Oncology
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 20597029 European Society for Medical Oncology
    ESMO Open 20597029 Kura Oncology, Inc., The Author(s)
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 2059-7029 European Society for Medical Oncology
    ESMO Open 20597029 2022
    ESMO Open 2059-7029 BMJ Publishing Group Ltd.
    ESMO Open 2059-7029 BMJ Group
    ESMO Open 2059-7029 BMJ Group